TABLE 2.
Inhibitory effects of CI-959 and CI-959-A on proliferation of transformed T cells
| Compound | IC50
(μM)a
|
|||||
|---|---|---|---|---|---|---|
| HTLV-I-infected cell
line
|
T-cell lymphoma line
|
|||||
| HT-1 | HT-2 | HT-3 | Jurkat | CCRF-CEM | MOLT-4 | |
| CI-959 | >10.0 | >10.0 | >10.0 | >10.0 | >10.0 | >10.0 |
| CI-959-A | >10.0 | >10.0 | >10.0 | 9.9 ± 0.3 | 8.2 ± 0.5 | >10.0 |
a
The 50% inhibitory concentrations (IC50s) of CI-959 and CI-959-A were determined by quantification of the inhibition of proliferation of HTLV-I-infected CD4+ cell lines and T-cell lymphoma lines. The proliferation of cell lines cultured for 4 days in the absence of compounds was 6,728 ± 512 cpm for HT-1 (2 × 104/well), 1,304 ± 1,859 cpm for HT-2 (2 × 104/well), 7,135 ± 990 cpm for HT-3 (2 × 104/well), 14,541 ± 7,618 cpm for Jurkat (2 × 104/well), 10,990 ± 4,619 cpm for CCRF-CEM (2 × 104/well), and 19,185 ± 8,003 cpm for MOLT-4 (2 × 104/well). Values are means ± standard deviations for three separate experiments.